ArticleCancer reports (Hoboken, N.J.)2024

Marked Response to Nivolumab by a Patient With SMARCA4-Deficient Undifferentiated Urothelial Carcinoma Showing High PD-L1 Expression: A Case Report.

Yohei Arihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.